Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent.
10.3346/jkms.2011.26.10.1299
- Author:
Ung KIM
1
;
Sang Hee LEE
;
Geu Ru HONG
;
Jong Seon PARK
;
Dong Gu SHIN
;
Young Jo KIM
;
Jae Sik JANG
;
Tae Hyun YANG
;
Dae Kyeong KIM
;
Dong Soo KIM
;
Dong Kie KIM
;
Sang Hoon SEOL
;
Doo Il KIM
;
Yoon Kyung CHO
;
Hyung Seop KIM
;
Chang Wook NAM
;
Seung Ho HUR
;
Kwon Bae KIM
Author Information
1. Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea. pjs@med.yu.ac.kr
- Publication Type:Original Article
- Keywords:
Drug-Eluting Stents;
Long Lesion;
Long-Term, Outcomes
- MeSH:
Aged;
Aged, 80 and over;
Coronary Angiography;
Coronary Artery Disease/*therapy;
*Drug-Eluting Stents/adverse effects;
Female;
Follow-Up Studies;
Humans;
Male;
Middle Aged;
Paclitaxel/*administration & dosage/adverse effects;
Sirolimus/*administration & dosage/adverse effects;
Treatment Outcome
- From:Journal of Korean Medical Science
2011;26(10):1299-1304
- CountryRepublic of Korea
- Language:English
-
Abstract:
Limited data are available on the long-term clinical efficacy of drug-eluting stent (DES) in diffuse long lesions. From May 2006 to May 2007, a total of 335 consecutive patients (374 lesions) were underwent percutaneous coronary intervention with implantation of long DES (> or = 30 mm) in real world practice. Eight-month angiographic outcomes and 2-yr clinical outcomes were compared between SES (n = 218) and PES (n = 117). Study endpoints were major adverse cardiac events including cardiac death, myocardial infarction, target-lesion revascularization, target-vessel revascularization and stent thrombosis. Baseline characteristics were similar in the two groups as were mean stent length (44.9 +/- 15.2 mm in SES and 47.4 +/- 15.9 in PES, P = 0.121). Late loss at 8 months follow-up was significantly lower in SES than in PES group (0.4 +/- 0.6 mm in SES vs 0.7 +/- 0.8 mm in PES, P = 0.007). Mean follow-up duration was 849 +/- 256 days, and 2-yr cumulative major adverse cardiac events were significantly lower in the SES than in the PES group (5.5% in SES vs 15.4% in PES, P = 0.003). In conclusion, long-term DES use in diffuse long coronary lesions is associated with favorable results, with SES being more effective and safer than PES in this real-world clinical experience.
